Ventyx Biosciences (NASDAQ:VTYX) Lowered to “Hold” Rating by UBS Group

UBS Group downgraded shares of Ventyx Biosciences (NASDAQ:VTYX) from a strong-buy rating to a hold rating in a report released on Thursday morning,Zacks.com reports.

A number of other research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Canaccord Genuity Group lowered shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $16.00 to $14.00 in a research report on Thursday. Clear Str cut shares of Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Piper Sandler lowered shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a research note on Thursday. Finally, Lifesci Capital restated a “market perform” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday. Eight equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ventyx Biosciences has an average rating of “Reduce” and a consensus target price of $14.86.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX opened at $13.81 on Thursday. The stock has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00. The stock’s 50 day moving average price is $9.27 and its 200 day moving average price is $5.28.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. On average, sell-side analysts expect that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Activity

In other news, CEO Raju Mohan sold 47,345 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This trade represents a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Nuss sold 12,675 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the sale, the insider owned 489,481 shares in the company, valued at $3,778,793.32. This represents a 2.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 14.49% of the company’s stock.

Institutional Trading of Ventyx Biosciences

A number of hedge funds have recently modified their holdings of VTYX. Affinity Asset Advisors LLC purchased a new position in shares of Ventyx Biosciences during the second quarter valued at $9,707,000. Marshall Wace LLP purchased a new position in Ventyx Biosciences during the 2nd quarter valued at about $5,129,000. Baker BROS. Advisors LP acquired a new position in shares of Ventyx Biosciences in the 3rd quarter valued at about $3,182,000. AQR Capital Management LLC increased its holdings in shares of Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock valued at $1,012,000 after purchasing an additional 794,401 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Ventyx Biosciences by 19.2% in the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after purchasing an additional 607,725 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

More Ventyx Biosciences News

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.